microdosing glp 1 noom Is GLP-1 for weight loss safe and effective? Noom Introduces a Microdosed GLP-1

The post hoc analysis of pooled data from the Semaglutide Treatment Effect in People with Obesity (STEP) 1, 2, 3, and 5 trials indicated that semaglutide treatment at 2.4 mg did not increase the risk of depressive symptoms or suicidal ideation compared to placebo, while demonstrating a statistically significant yet clinically negligible decrease in depressive symptoms [75]

Gilliam, A

Slows Digestion: Stabilizes blood sugar and minimizes cravings

In order to evaluate the full scope of information available, no papers were excluded on the basis of geographical context or population

1 The findings showed: Those not taking GLP-1 medications showed significantly more MS disease progression Higher risk of brainstem dysfunction (4.36% risk difference) Higher risk of cerebellar dysfunction (4.54% risk difference) Higher risk of bowel and bladder dysfunction (4.98% risk difference) As a retrospective analysis, this study has limitations including potential confounding factors, and definitive randomised controlled trials are needed to confirm any disease-modifying effects of GLP-1 medications in MS